Checkpoint inhibitor

First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer

Retrieved on: 
Wednesday, June 23, 2021
Cancer, Clinical medicine, Infectious causes of cancer, Carcinoma, Transitional cell carcinoma, Aging-associated diseases, Transitional epithelium, Bladder cancer, Kidney cancer, Metástasis, Avelumab, Checkpoint inhibitor

The objective of the ZiP-UP (Zirconium-girentuximab PET in Urothelial Cancer Patients) study is to evaluate the feasibility of using TLX250-CDx PET/CT1 in the detection of localised and metastatic urothelial carcinoma or bladder cancer.

Key Points: 
  • The objective of the ZiP-UP (Zirconium-girentuximab PET in Urothelial Cancer Patients) study is to evaluate the feasibility of using TLX250-CDx PET/CT1 in the detection of localised and metastatic urothelial carcinoma or bladder cancer.
  • The trial will recruit 20 patients over 12 months: ten patients with known metastatic urothelial carcinoma or bladder cancer; and ten patients that require primary staging of localised urothelial carcinoma or bladder cancer.
  • Telix CEO, Dr Christian Behrenbruch added, We are pleased that a first patient has been dosed in this study exploring the clinical utility of TLX250-CDx to image other cancers, beyond renal cancer, and in indications where conventional imaging has limitations.
  • Bladder cancer is the sixth most commonly occurring cancer in men, and the tenth most common cancer overall worldwide.2 In 2020, 573,278 people worldwide were diagnosed with bladder cancer and 212,536 people died from their disease.3 Urothelial carcinoma (or UCC) accounts for ~90% of all bladder cancers.

Virion Therapeutics Announces Presentation of Preclinical Data of VRON-0200, a Chronic Hepatitis B Virus (HBV) Therapeutic Vaccine, at the International Liver Congress (ILC)

Retrieved on: 
Monday, June 21, 2021
Medicine, Clinical medicine, Cancer immunotherapy, Medical specialties, Immune system, Immunotherapy, Virotherapy, Checkpoint inhibitor, European Association for the Study of the Liver, Virus

These results were only observed if Virions novel checkpoint inhibitor, gD, was present in the vaccine.This oral platform presentation was selected by the EASL-ILC Organizing Committee as a Best of ILC for highlight at the meeting.

Key Points: 
  • These results were only observed if Virions novel checkpoint inhibitor, gD, was present in the vaccine.This oral platform presentation was selected by the EASL-ILC Organizing Committee as a Best of ILC for highlight at the meeting.
  • Data to be presented at the EASL-ILC meeting:
    The above presentation will be available on June 25, 2021, via the EASL-ILC meeting website, https://easl.eu/event/the-international-liver-congress-2021 .
  • Virion Therapeutics, LLC, is a science driven company developing innovative immune-based treatments for virally associated cancers and chronic viral infections utilizing the first genetically encoded checkpoint inhibitor given via vaccination.
  • Our novel T cell-based immunotherapies induce potent, diverse and sustained T cell-mediated immune responses, allowing us to target common diseases with unmet medical needs.

Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, Immune system, Medical specialties, Immunology, Tumor microenvironment, Immune checkpoint, Checkpoint inhibitor, Macrophage, Programmed cell death protein 1, Cancer immunotherapy

By reversing immunosuppressive tumor microenvironments, rigosertib overcame pro-tumor resistance mechanisms and synergistically enhanced the efficacy of immune checkpoint blockade in a difficult-to-treat murine melanoma model.

Key Points: 
  • By reversing immunosuppressive tumor microenvironments, rigosertib overcame pro-tumor resistance mechanisms and synergistically enhanced the efficacy of immune checkpoint blockade in a difficult-to-treat murine melanoma model.
  • These compelling findings provide preclinical proof-of-concept for rigosertib-immune checkpoint blockade combination therapy and strongly support its evaluation in clinical trials.
  • Key data and conclusions from the recent publication include:
    Rigosertib treatment reduced the frequency of pro-tumor CD206+ M2-like macrophages in the TME.
  • Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer.

Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors

Retrieved on: 
Thursday, June 17, 2021
Oncology, Health, FDA, General Health, Research, Science, Biotechnology, Clinical medicine, Medical specialties, Immune system, Medicine, Clusters of differentiation, Cancer immunotherapy, Checkpoint inhibitor, Programmed cell death protein 1, CTLA-4, PD-1 and PD-L1 inhibitors

XTX101 is a tumor-selective anti-CTLA-4 monoclonal antibody designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies by overcoming their historical potency and tolerability limitations.

Key Points: 
  • XTX101 is a tumor-selective anti-CTLA-4 monoclonal antibody designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies by overcoming their historical potency and tolerability limitations.
  • This first IND acceptance for Xilio represents a significant milestone for us as we transition to a clinical-stage organization, said Marty Huber, M.D., chief medical officer of Xilio Therapeutics.
  • It is well known that checkpoint inhibitors hold significant clinical potential; however, treatment with anti-CTLA-4 therapies has been limited because of challenging autoimmune toxicities.
  • XTX101 has also demonstrated enhanced tumor growth inhibition and tolerability when administered in combination with an anti-PD-1 in vivo.

ImmunoGenesis Announces Publication of Phase 1 Data on its Hypoxia-Reversal Agent Highlighting Efficacy and Genetic Expression Correlatives in Advanced Cancer

Retrieved on: 
Wednesday, June 16, 2021
Clinical medicine, Medicine, Cancer, Cancer immunotherapy, Oncology, Virotherapy, Bristol-Myers Squibb, Ipilimumab, Prostate cancer, Immunotherapy, Checkpoint inhibitor, Evofosfamide

"A hostile tumor metabolism is a major source of immune resistance in certain tumors,"said James Barlow , ImmunoGenesis President and CEO.

Key Points: 
  • "A hostile tumor metabolism is a major source of immune resistance in certain tumors,"said James Barlow , ImmunoGenesis President and CEO.
  • "Evofosfamide, with the demonstrated ability to reduce tumor hypoxia, can be a critical component of facilitating immunotherapy efficacy in these tumors.
  • "These exciting Phase 1 data support preclinical observations in which evofosfamide reversed tumor hypoxia and facilitated the efficacy of checkpoint inhibition.
  • The Phase 1 (NCT03098160), dose-escalation study tested evofosfamide in combination with ipilimumab administered in four three-week cycles inheavily pre-treated patients with castration-resistant prostate cancer, advanced pancreatic cancer, immunotherapy-resistant melanoma, and advanced HPV-negative head and neck cancer.

AIM ImmunoTech’s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2

Retrieved on: 
Monday, June 14, 2021
Clinical medicine, Medicine, Medical specialties, Rintatolimod, Cancers, Oncology, Checkpoint inhibitor

Cancers is a peer-reviewed, open access journal of oncology published semimonthly online by MDPI.

Key Points: 
  • Cancers is a peer-reviewed, open access journal of oncology published semimonthly online by MDPI.
  • van Eijck, MD, PhD, the lead investigator for an Early Access Program at Erasmus Medical Center in the Netherlands, where Ampligen is being used to treat patients with late-stage pancreatic cancer.
  • I do think Ampligen fully deserves to be developed for potential approval in the treatment of viral infections, including COVID-19.
  • The granted claims include, but are not limited to, the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors (e.g.

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies

Retrieved on: 
Monday, June 14, 2021
Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Immune system, Antineoplastic drugs, Breakthrough therapy, Orphan drugs, Pembrolizumab, Checkpoint inhibitor, Myelodysplastic syndrome, Oncology

The two randomized Phase 2 studies, ASPEN-03 and ASPEN-04, are potentially registrational with patient enrollment unimpacted in either study.

Key Points: 
  • The two randomized Phase 2 studies, ASPEN-03 and ASPEN-04, are potentially registrational with patient enrollment unimpacted in either study.
  • ALX Oncology is advancing ALX148 into two randomized Phase 2 studies in subjects with HNSCC in combination with pembrolizumab, marketed as KEYTRUDA, the market leading anti-programmed cell death protein-1, or PD-1, checkpoint inhibitor, with or without chemotherapy.
  • ALX Oncology intends to continue clinical development of ALX148 for the treatment of multiple solid tumor indications and hematologic malignances, including AML and myelodysplastic syndromes (MDS).
  • Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Hummingbird Bioscience to Speak at 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"

Retrieved on: 
Monday, June 14, 2021
Immune system, Immunology, Medical specialties, Organ systems, Programmed cell death protein 1, Immune checkpoint, Vista, Checkpoint inhibitor, Cancer immunotherapy

Hummingbird will be speaking in the following sessions:

Key Points: 
  • Hummingbird will be speaking in the following sessions:
    "The presence of VISTA is increasingly implicated as a resistance mechanism to other immune checkpoint therapies, including anti-PD-1 and anti-CTLA-4 antibodies.
  • This conference is an excellent opportunity to share insights and knowledge, including Hummingbird's experience with our highly differentiated clinical stage anti-VISTA antibody, HMBD-002," said Dr Boyd-Kirkup.
  • Pre-clinical studies have shown that HMBD-002 as a monotherapy inhibits tumor growth and significantly prolongs survival, with no observed toxicity.
  • For more information, please visit www.hummingbirdbioscience.com , and follow Hummingbird on LinkedIn and Twitter (@hummingbirdbio).

New Insights on Sarcomatoid Kidney Cancer: Roswell Park Reports Clear Benefit from Checkpoint Inhibitors

Retrieved on: 
Tuesday, June 8, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Medical specialties, Kidney cancer, Lung cancer, Checkpoint inhibitor, Oncology, Cancer

"The benefits persisted even if the immune checkpoint inhibitor was administered in the second line or beyond, and among patients with non-clear cell histology the hardest-to-treat sarcomatoid kidney cancers."

Key Points: 
  • "The benefits persisted even if the immune checkpoint inhibitor was administered in the second line or beyond, and among patients with non-clear cell histology the hardest-to-treat sarcomatoid kidney cancers."
  • "This study clearly establishes immune checkpoint inhibitors as the preferred therapy for patients with advanced sarcomatoid kidney cancer," says Saby George, MD, FACP, Professor of Oncology and Medicine and Director of Network Clinical Trials at Roswell Park.
  • They also observed significant benefit from treatment with ICIs among patients with non-clear cell or mixed-histology sarcomatoid kidney cancer.
  • "Overall survival benefit was maintained in patients who received immune checkpoint inhibitors in the second line, after other initial treatment, or later."

Osel Announces Positive Results from Phase 1b Trial of Live Biotherapeutic Product CBM588 in Combination with Checkpoint Inhibitor (CPI) Therapy in Metastatic Renal Cell Carcinoma

Retrieved on: 
Monday, June 7, 2021
Science, Biotechnology, Research, Pharmaceutical, Alternative medicine, Oncology, Health, Clinical trials, Clinical medicine, Drugs, Medicine, Bristol-Myers Squibb, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Cancer immunotherapy, Nivolumab, Ipilimumab, Checkpoint inhibitor, Renal cell carcinoma, Osel Inc., Miyarisan, OSEL INC., MIYARISAN

The presentation titled First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM588 in patients with metastatic renal cell carcinoma (Abstract #4513) is part of the session titled Genitourinary Cancer Kidney and Bladder.

Key Points: 
  • The presentation titled First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM588 in patients with metastatic renal cell carcinoma (Abstract #4513) is part of the session titled Genitourinary Cancer Kidney and Bladder.
  • We are very pleased with results generated from this clinical study, said Thomas Parks, Ph.D., Head of Development at Osel.
  • There is considerable interest in microbiome modulation to enhance immune checkpoint inhibitor efficacy that is more consistent and scalable than fecal transplants.
  • These data are an encouraging indicator of potential patient benefit in an initial indication of metastatic RCC.